EU/3/18/2047

About

On 31 July 2018, orphan designation (EU/3/18/2047) was granted by the European Commission to Glycomine SARL, France, for liposomal mannose-1-phosphate for the treatment of phosphomannomutase 2-congenital disorder of glycosylation.

Key facts

Active substance
liposomal mannose-1-phosphate
Disease / condition
treatment of phosphomannomutase 2-congenital disorder of glycosylation
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2047

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Glycomine SARL
12 rue Anselme
93400 Saint Ouen
France
Tel. +33 7 6702 4099
E-mail: prioux@glycomine.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating